A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease

被引:0
作者
Rugeri, Lucia [1 ]
Thomas, Will
Schirner, Kathrin
Heyder, Lisa
Auerswald, Guenter
机构
[1] Hop Cardiol, Unite Hemostase Clin, Hosp Civils Lyon, Lyon, France
关键词
blood products; factor VIII; systematic review; von Willebrand disease; von Willebrand factor; WFH; 2021; GUIDELINES; INHIBITOR DEVELOPMENT; VENOUS THROMBOSIS; CLINICAL-EFFICACY; MANAGEMENT; BIOSTATE(R); DIAGNOSIS; PHARMACOKINETICS; POPULATION; PREVENTION;
D O I
10.1055/a-2253-9701
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background For the treatment of von Willebrand disease (VWD), von Willebrand factor (VWF) concentrates can be used in on-demand, long-term prophylaxis, and surgical prophylaxis regimens. Methods This systematic literature review was conducted to evaluate the efficacy, consumption, and safety of plasma-derived human coagulation FVIII/human VWF (pdVWF/FVIII; Voncento/Biostate) for the treatment of patients with any inherited VWD type. An electronic search was conducted in MEDLINE and Cochrane Library databases on VWD therapies. All retrieved publications were assessed against predefined inclusion/exclusion criteria following the Cochrane group recommendations. Associated pharmacovigilance data were collected across the same time period. Results Eleven publications from eight study cohorts were identified for data retrieval. All were from multicenter studies and included both pediatric and adult patients. Eight publications included evaluations of the efficacy of pdVWF/FVIII for on-demand treatment, eight included long-term prophylactic treatment, and eight included surgical prophylaxis. Treatment protocols and VWF administration methods differed between studies, as did safety evaluations. The clinical response was rated as excellent/good for on-demand treatment in 66 to 100% of nonsurgical bleeds, 89 to 100% in the treatment of breakthrough bleeds during long-term prophylaxis treatment, and hemostatic efficacy in surgical procedures was 75 to 100%. Pharmacovigilance data confirmed a low incidence of adverse events in treated patients. Conclusion This review provides a comprehensive summary of studies that evaluated the use of pdVWF/FVIII in VWD demonstrating the long-term effectiveness and safety of this pdVWF/FVIII across all ages, types of VWD, and treatment settings.
引用
收藏
页码:828 / 841
页数:14
相关论文
共 41 条
  • [1] [Anonymous], IDENTIFIER EUDRACT 2
  • [2] [Anonymous], SUMMARY PRODUCTS CHA
  • [3] [Anonymous], GUIDELINE CLIN INVES
  • [4] Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
    Auerswald, Guenter
    Khayat, Claudia Djambas
    Stasyshyn, Oleksandra
    Iosava, Genadi
    Romashevskaya, Irina
    Lopez, Marta Julia
    Seifert, Wilfried
    Rogosch, Tobias
    [J]. JOURNAL OF BLOOD MEDICINE, 2020, 11 : 213 - 225
  • [5] Principles of care for the diagnosis and treatment of von Willebrand disease
    Castaman, Giancarlo
    Goodeve, Anne
    Eikenboom, Jeroen
    [J]. HAEMATOLOGICA, 2013, 98 (05) : 667 - 674
  • [6] Assessing risk factors: prevention of inhibitors in haemophilia
    Chambost, H.
    [J]. HAEMOPHILIA, 2010, 16 : 10 - 15
  • [7] clinicaltrialsregister, EU Clinical Trials Register.
  • [8] ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
    Connell, Nathan T.
    Flood, Veronica H.
    Brignardello-Petersen, Romina
    Abdul-Kadir, Rezan
    Arapshian, Alice
    Couper, Susie
    Grow, Jean M.
    Kouides, Peter
    Laffan, Michael
    Lavin, Michelle
    Leebeek, Frank W. G.
    O'Brien, Sarah H.
    Ozelo, Margareth C.
    Tosetto, Alberto
    Weyand, Angela C.
    James, Paula D.
    Kalot, Mohamad A.
    Husainat, Nedaa
    Mustafa, Reem A.
    [J]. BLOOD ADVANCES, 2021, 5 (01) : 301 - 325
  • [9] Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies
    Coppola, A.
    Santoro, C.
    Tagliaferri, A.
    Franchini, M.
    Di Minno, G.
    [J]. HAEMOPHILIA, 2010, 16 : 13 - 19
  • [10] d'Oiron R., 2022, HAEMOPHILIA, V28, P25